Your browser doesn't support javascript.
loading
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.
Tvingsholm, Siri Amanda; Frej, Marcus Svensson; Rafa, Vibeke Mindahl; Hansen, Ulla Kring; Ormhøj, Maria; Tyron, Alexander; Jensen, Agnete W P; Kadivar, Mohammad; Bentzen, Amalie Kai; Munk, Kamilla K; Aasbjerg, Gitte N; Ternander, Jeppe S H; Heeke, Christina; Tamhane, Tripti; Schmess, Christian; Funt, Samuel A; Kjeldsen, Julie Westerlin; Kverneland, Anders Handrup; Met, Özcan; Draghi, Arianna; Jakobsen, Søren Nyboe; Donia, Marco; Marie Svane, Inge; Hadrup, Sine Reker.
Afiliación
  • Tvingsholm SA; Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
  • Frej MS; PokeAcell Aps, BioInnovation Institute, Copenhagen, Denmark.
  • Rafa VM; Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
  • Hansen UK; PokeAcell Aps, BioInnovation Institute, Copenhagen, Denmark.
  • Ormhøj M; Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
  • Tyron A; Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
  • Jensen AWP; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Herlev Hospital, Herlev, Denmark.
  • Kadivar M; Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
  • Bentzen AK; Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
  • Munk KK; Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
  • Aasbjerg GN; Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
  • Ternander JSH; PokeAcell Aps, BioInnovation Institute, Copenhagen, Denmark.
  • Heeke C; Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
  • Tamhane T; Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
  • Schmess C; NMI Natural and Medical Science Institute, University of Tübingen, Tubingen, Germany.
  • Funt SA; Deptartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Kjeldsen JW; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Herlev Hospital, Herlev, Denmark.
  • Kverneland AH; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Herlev Hospital, Herlev, Denmark.
  • Met Ö; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Herlev Hospital, Copenhagen, Denmark.
  • Draghi A; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Herlev Hospital, Herlev, Denmark.
  • Jakobsen SN; Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
  • Donia M; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Herlev Hospital, Herlev, Denmark.
  • Marie Svane I; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Herlev Hospital, Herlev, Denmark.
  • Hadrup SR; Department of Health Technology, Technical University of Denmark, Lyngby, Denmark sirha@dtu.dk.
J Immunother Cancer ; 11(8)2023 08.
Article en En | MEDLINE | ID: mdl-37586765
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Primarias Secundarias / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Primarias Secundarias / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Reino Unido